Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Modulation of the UGT2B7 enzyme activity by C-terminally truncated proteins derived from alternative splicing.

Ménard V, Collin P, Margaillan G, Guillemette C.

Drug Metab Dispos. 2013 Dec;41(12):2197-205. doi: 10.1124/dmd.113.053876. Epub 2013 Oct 2.

2.

Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer.

Ménard V, Lévesque E, Chen S, Eap O, Joy MS, Ekström L, Rane A, Guillemette C.

Pharmacogenet Genomics. 2013 Dec;23(12):684-96. doi: 10.1097/FPC.0000000000000008.

PMID:
24128937
3.

Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new splicing event at the UGT1A locus.

Lévesque E, Girard H, Journault K, Lépine J, Guillemette C.

Hepatology. 2007 Jan;45(1):128-38.

PMID:
17187418
4.

Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants.

Ménard V, Eap O, Roberge J, Harvey M, Lévesque E, Guillemette C.

Pharmacogenet Genomics. 2011 Oct;21(10):631-41. doi: 10.1097/FPC.0b013e3283498147.

PMID:
21881541
5.

The relative protein abundance of UGT1A alternative splice variants as a key determinant of glucuronidation activity in vitro.

Rouleau M, Roberge J, Falardeau SA, Villeneuve L, Guillemette C.

Drug Metab Dispos. 2013 Apr;41(4):694-7. doi: 10.1124/dmd.112.050468. Epub 2013 Jan 29.

6.

Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro.

Bellemare J, Rouleau M, Girard H, Harvey M, Guillemette C.

Drug Metab Dispos. 2010 Oct;38(10):1785-9. doi: 10.1124/dmd.110.034835. Epub 2010 Jul 7.

7.

Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans.

Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Têtu B, Guillemette C.

J Pathol. 2011 Feb;223(3):425-35. doi: 10.1002/path.2805. Epub 2010 Oct 29.

8.

Protein-protein interactions between the bilirubin-conjugating UDP-glucuronosyltransferase UGT1A1 and its shorter isoform 2 regulatory partner derived from alternative splicing.

Rouleau M, Collin P, Bellemare J, Harvey M, Guillemette C.

Biochem J. 2013 Feb 15;450(1):107-14. doi: 10.1042/BJ20121594.

PMID:
23148825
9.

Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity.

Girard H, Lévesque E, Bellemare J, Journault K, Caillier B, Guillemette C.

Pharmacogenet Genomics. 2007 Dec;17(12):1077-89.

PMID:
18004212
10.

Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Jones NR, Sun D, Freeman WM, Lazarus P.

J Pharmacol Exp Ther. 2012 Sep;342(3):720-9. doi: 10.1124/jpet.112.192658. Epub 2012 Jun 1.

11.

Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions.

Bellemare J, Rouleau M, Harvey M, Guillemette C.

J Biol Chem. 2010 Feb 5;285(6):3600-7. doi: 10.1074/jbc.M109.083139. Epub 2009 Dec 8.

13.

Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine.

Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, Manns MP.

J Biol Chem. 2000 Nov 17;275(46):36164-71.

14.

Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines.

Bellemare J, Rouleau M, Harvey M, Têtu B, Guillemette C.

Pharmacogenomics J. 2010 Oct;10(5):431-41. doi: 10.1038/tpj.2009.64. Epub 2009 Dec 8.

PMID:
19997083
15.

Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7.

Strassburg CP, Barut A, Obermayer-Straub P, Li Q, Nguyen N, Tukey RH, Manns MP.

J Hepatol. 2001 Jun;34(6):865-72.

PMID:
11451170
16.
17.

Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.

Dostalek M, Court MH, Hazarika S, Akhlaghi F.

Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1.

18.

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.

Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ.

Pharmacogenet Genomics. 2008 Aug;18(8):683-97. doi: 10.1097/FPC.0b013e3283037fe4.

19.

Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin.

Sadeque AJ, Usmani KA, Palamar S, Cerny MA, Chen WG.

Drug Metab Dispos. 2012 Apr;40(4):772-8. doi: 10.1124/dmd.111.043448. Epub 2012 Jan 18.

20.

Characterization of UDP-glucuronosyltransferases involved in glucuronidation of diethylstilbestrol in human liver and intestine.

Zhu L, Ge G, Liu Y, Guo Z, Peng C, Zhang F, Cao Y, Wu J, Fang Z, Liang X, Yang L.

Chem Res Toxicol. 2012 Dec 17;25(12):2663-9. doi: 10.1021/tx300310k. Epub 2012 Nov 13.

PMID:
23126256

Supplemental Content

Support Center